Asthma Trial, Completed (NCT00231114)

Asthma Trial, Completed NCT00231114 Sponsor: Boston Scientific Corporation Condition: Asthma

Printed from Voxsanity (voxsanity.com.au) — NCT00231114 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Asthma

Trial results

AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

According to the results reported on ClinicalTrials.gov, this trial enrolled 297 people with asthma — 196 in the Alair (treatment) group and 101 in the sham (control) group, where the sham group went through a similar procedure without the active treatment. The trial was measuring changes in asthma-related quality of life over 12 months, along with several other asthma-related measures such as symptom-free days, symptom scores, and use of quick-relief ("rescue") medication. The reported data shows that for the main outcome — a quality of life questionnaire scored from 1 to 7, where higher numbers mean better quality of life — both groups reported improvements from their starting scores. The Alair group's average score increased by 1.35 points, while the sham group's increased by 1.16 points. For the other reported measures, both groups also showed changes in the same direction: the percentage of symptom-free days increased by about 24% in the Alair group and 21% in the sham group; overall symptom scores fell by 1.7 points (Alair) and 1.6 points (sham) out of a maximum possible score of 18; weekly puffs of rescue medication decreased by about 6 puffs (Alair) and 4.3 puffs (sham); the percentage of days rescue medication was used fell by 24% (Alair) and 22% (sham); and an asthma control questionnaire score (lower is better) dropped by 0.82 points (Alair) and 0.77 points (sham). These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.

View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 23998657) ↗

These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You are between 18 and 65 years old.
You have asthma and are currently taking two types of regular medication: an inhaled corticosteroid (a preventer inhaler) AND a long-acting bronchodilator (a long-acting reliever inhaler).
Your lung function, measured by a breathing test before using a bronchodilator, is at 60% or more of the expected level for someone your age and size.
You show a significant sensitivity to airways during a specific breathing challenge test using a substance called methacholine (confirm with trial site).
You have had asthma symptoms on at least two days during a 4-week diary recording period at the start of the trial.
You have not smoked for at least 1 year, and if you were previously a smoker, your total lifetime smoking history is less than 10 pack-years (confirm with trial site).

Who may not be able to join:

Your lung function after using a bronchodilator is less than 65% of the expected level.
You have been hospitalised 3 or more times for serious asthma attacks in the past year, or have had a life-threatening asthma episode requiring a breathing tube or intensive care unit admission in the past 2 years.
You have had 3 or more chest infections in the past 12 months that needed antibiotic treatment.
You have needed steroid tablets or liquid (taken by mouth) to treat your asthma 4 or more times in the past 12 months.
You have a known allergy or sensitivity to medications used during a bronchoscopy procedure (a camera examination of the airways), such as local anaesthetic or sedative drugs.
You have a known allergy or bad reaction to methacholine or similar substances.
You have other medical conditions that may affect eligibility (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 23 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Narinder S Shargill, PhD, Asthmatx, Inc.

Australian sites

John Hunter Hospital, New Lambton Heights, New South Wales

Sir Charles Gairdner Hospital, Perth, Western Australia

Royal Adelaide Hospital, Adelaide,

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I found the following past clinical trial relevant to my condition, and wanted to raise it with you. It is no longer recruiting, but I wanted to ask whether similar active trials exist, or whether its results are relevant to my care:

Trial: NCT00231114

Sponsor: Boston Scientific Corporation

Phase: Not Applicable

Status: Completed

Condition: Asthma

More information: https://clinicaltrials.gov/study/NCT00231114

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You are between 18 and 65 years old.
You have asthma and are currently taking two types of regular medication: an inhaled corticosteroid (a preventer inhaler) AND a long-acting bronchodilator (a long-acting reliever inhaler).
Your lung function, measured by a breathing test before using a bronchodilator, is at 60% or more of the expected level for someone your age and size.
You show a significant sensitivity to airways during a specific breathing challenge test using a substance called methacholine (confirm with trial site).
You have had asthma symptoms on at least two days during a 4-week diary recording period at the start of the trial.
You have not smoked for at least 1 year, and if you were previously a smoker, your total lifetime smoking history is less than 10 pack-years (confirm with trial site).

Who may not be able to join:

Your lung function after using a bronchodilator is less than 65% of the expected level.
You have been hospitalised 3 or more times for serious asthma attacks in the past year, or have had a life-threatening asthma episode requiring a breathing tube or intensive care unit admission in the past 2 years.
You have had 3 or more chest infections in the past 12 months that needed antibiotic treatment.
You have needed steroid tablets or liquid (taken by mouth) to treat your asthma 4 or more times in the past 12 months.
You have a known allergy or sensitivity to medications used during a bronchoscopy procedure (a camera examination of the airways), such as local anaesthetic or sedative drugs.
You have a known allergy or bad reaction to methacholine or similar substances.
You have other medical conditions that may affect eligibility (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 23 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Completed

Phase

Not Applicable

Sponsor

Boston Scientific Corporation

Registry

ClinicalTrials.gov

Start date

1 September 2005

Est. completion

1 August 2008

Where this trial is recruiting

🇦🇺 Australia 🇧🇷 Brazil 🇨🇦 Canada 🇩🇰 Denmark 🇳🇱 Netherlands 🇬🇧 United Kingdom 🇺🇸 United States

3 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Integrated Asthma Quality of Life Questionnaire (AQLQ) Score (Change From Baseline)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov